Logo image of CPIX

CUMBERLAND PHARMACEUTICALS (CPIX) Stock Price, Quote, News and Overview

NASDAQ:CPIX - Nasdaq - US2307701092 - Common Stock - Currency: USD

5.31  -0.64 (-10.76%)

After market: 5.211 -0.1 (-1.86%)

CPIX Quote, Performance and Key Statistics

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (2/21/2025, 8:10:42 PM)

After market: 5.211 -0.1 (-1.86%)

5.31

-0.64 (-10.76%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High7.19
52 Week Low1.04
Market Cap74.55M
Shares14.04M
Float7.84M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-11 2025-03-11
IPO08-11 2009-08-11


CPIX short term performance overview.The bars show the price performance of CPIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300 400

CPIX long term performance overview.The bars show the price performance of CPIX in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100

The current stock price of CPIX is 5.31 USD. In the past month the price increased by 112.4%. In the past year, price increased by 148.13%.

CUMBERLAND PHARMACEUTICALS / CPIX Daily stock chart

CPIX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.53 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.62 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.81 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About CPIX

Company Profile

CPIX logo image Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.

Company Info

CUMBERLAND PHARMACEUTICALS

2525 W End Ave Ste 950

Nashville TENNESSEE 37203 US

CEO: A. J. Kazimi

Employees: 91

Company Website: https://www.cumberlandpharma.com/

Investor Relations: http://investor.shareholder.com/cpix/

Phone: 16152550068

CUMBERLAND PHARMACEUTICALS / CPIX FAQ

What is the stock price of CUMBERLAND PHARMACEUTICALS today?

The current stock price of CPIX is 5.31 USD. The price decreased by -10.76% in the last trading session.


What is the ticker symbol for CUMBERLAND PHARMACEUTICALS stock?

The exchange symbol of CUMBERLAND PHARMACEUTICALS is CPIX and it is listed on the Nasdaq exchange.


On which exchange is CPIX stock listed?

CPIX stock is listed on the Nasdaq exchange.


What is CUMBERLAND PHARMACEUTICALS worth?

CUMBERLAND PHARMACEUTICALS (CPIX) has a market capitalization of 74.55M USD. This makes CPIX a Micro Cap stock.


How many employees does CUMBERLAND PHARMACEUTICALS have?

CUMBERLAND PHARMACEUTICALS (CPIX) currently has 91 employees.


Should I buy CUMBERLAND PHARMACEUTICALS (CPIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CUMBERLAND PHARMACEUTICALS (CPIX) stock pay dividends?

CPIX does not pay a dividend.


When does CUMBERLAND PHARMACEUTICALS (CPIX) report earnings?

CUMBERLAND PHARMACEUTICALS (CPIX) will report earnings on 2025-03-11.


What is the Price/Earnings (PE) ratio of CUMBERLAND PHARMACEUTICALS (CPIX)?

CUMBERLAND PHARMACEUTICALS (CPIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).


What is the Short Interest ratio of CUMBERLAND PHARMACEUTICALS (CPIX) stock?

The outstanding short interest for CUMBERLAND PHARMACEUTICALS (CPIX) is 2.44% of its float. Check the ownership tab for more information on the CPIX short interest.


CPIX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to CPIX. When comparing the yearly performance of all stocks, CPIX is one of the better performing stocks in the market, outperforming 99.27% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CPIX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CPIX. CPIX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CPIX Financial Highlights

Over the last trailing twelve months CPIX reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS decreased by -170.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.16%
ROE -43.87%
Debt/Equity 0.41
Chartmill High Growth Momentum
EPS Q2Q%-200%
Sales Q2Q%-9.91%
EPS 1Y (TTM)-170.83%
Revenue 1Y (TTM)-6.45%

CPIX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to CPIX. The Buy consensus is the average rating of analysts ratings from 6 analysts.


Ownership
Inst Owners14.87%
Ins Owners3.35%
Short Float %2.44%
Short Ratio0.05
Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A